ALT5 Sigma Corporation Share Price BOERSE MUENCHEN

Equities

5AR1

US47089W1045

Biotechnology & Medical Research

Real-time BOERSE MUENCHEN 03:43:06 17/07/2024 pm IST 5-day change 1st Jan Change
2.04 EUR +0.99% Intraday chart for ALT5 Sigma Corporation +14.77% +305.22%

Financials

Sales 2022 39.61M 36.31M 3.31B Sales 2023 - Capitalization 2.75M 2.52M 230M
Net income 2022 11M 10.08M 919M Net income 2023 -7M -6.42M -585M EV / Sales 2022 0.41 x
Net Debt 2022 12.02M 11.02M 1B Net Debt 2023 416K 381K 34.74M EV / Sales 2023 -
P/E ratio 2022
0.39 x
P/E ratio 2023
-0.28 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 99.07%
More Fundamentals * Assessed data
Dynamic Chart
1 week+14.77%
Current month-3.81%
1 month-9.01%
3 months-42.61%
6 months+300.00%
Current year+305.22%
More quotes
1 week
1.76
Extreme 1.76
2.18
1 month
1.69
Extreme 1.69
2.46
3 years
0.28
Extreme 0.2845
6.85
More quotes
Managers TitleAgeSince
Chief Executive Officer 69 01/15/01
Director of Finance/CFO 64 21/17/21
Chief Tech/Sci/R&D Officer - 29/20/29
Members of the board TitleAgeSince
Chief Executive Officer 69 01/15/01
Director/Board Member 75 01/15/01
Director/Board Member 40 01/18/01
More insiders
Date Price Change
17/24/17 2.04 +0.99%
16/24/16 2.02 +4.12%
15/24/15 1.94 -5.83%
12/24/12 2.06 +3.52%
11/24/11 1.99 +5.29%

Real-time BOERSE MUENCHEN, July 17, 2024 at 01:13 pm IST

More quotes
JanOne Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, acquiring, licensing, developing, partnering, and commercializing novel, no-opioid, and non-addictive therapies to address the large, unmet medical need for the treatment of pain and addiction. Its drug candidate, JAN101, is a patented oral, sustained-release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities, such as those with vascular complications of diabetes or Peripheral Artery Disease (PAD) and treats pain. Its drug candidate is a treatment for Peripheral Artery Disease. The Company operates through the Biotechnology segment, which is focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Company is also engaged in providing blockchain-powered technologies through its two platforms: ALT 5 Pay and ALT 5 Prime.
More about the company